


APR 30 2004

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: April 27, 2004 Signature:


(Lynn L. Janulis, Ph.D.)

PATENT

Attorney Docket No: 01017/35966C

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Han et al.

Application No.: 10/758,636

Filed: January 15, 2004

Art Unit: Not Yet Assigned

For: The Human E3 α Ubiquitin Ligase Family

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.56, the attention of the United States Patent and Trademark Office is hereby directed to the references listed on the attached Form PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

The Applicants request that the documents listed on the attached Form PTO/SB/08 be made of official record in the above-identified application and considered by the Examiner. Pursuant to 37 C.F.R. § 1.98(d), copies of all listed documents cited on Form PTO/SB/08 are not submitted herewith because they were previously submitted to the Patent Office in priority application U.S. Serial No. 09/724,126 filed on 11/28/00, now issued U.S. Patent No. 6,706,505, from which priority is claimed under 35 U.S.C. § 120. Should the Examiner desire additional copies of the documents, the Applicants will provide them upon request.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 C.F.R. § 1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein constitutes prior art under 35 U.S.C. §§ 102 or 103.

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. § 1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 C.F.R. § 1.98.

No fee is believed to be due under 37 C.F.R. §1.97(b) because this statement and Form Form PTO/SB/08 are being submitted before receipt of a first Office action on the merits in the above-identified patent application. However, should the Patent Office determine that a fee is due for consideration of this Information Disclosure Statement, the Patent Office is hereby authorized to charge that fee to Deposit Account 13-2855.

Dated: April 27, 2004

Respectfully submitted,

By 

Lynn M. Janulis, Ph.D.
Registration No.: 53,066
Agent for Applicants
MARSHALL, GERSTEIN & BORUN LLP
233 S. Wacker Drive, Suite 6300
Sears Tower
Chicago, Illinois 60606-6357
(312) 474-6300



PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
				Application Number	10/758,636
				Filing Date	January 15, 2004
				First Named Inventor	Hui-Quan Han
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	01017/35966C

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
A1	5,861,312	09-19-1999	Varshavsky et al.		
A2	6,706,505	03-16-2004	Han et al.		

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
B1	WO 98/23283		06-04-1998		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	C1	BARACOS et al., "Activation of the ATP-ubiquitin-proteasome pathway in skeletal muscle of cachetic rats bearing a hepatoma", <i>Am J Physiol</i> 268 (Endocrinol Metab):E996-1006, 1995.			
	C2	BARTEL et al., "The recognition component of the N-end rule pathway" <i>EMBO J</i> 9:3179-3189, 1990.			
	C3	CIECHANOVER, "The ubiquitin-proteasome pathway: on protein death and cell life", <i>EMBO J</i> 17:7151-7160, 1998.			
	C4	HILLIER et al., Database GenBank. Accession No. AI929033, Aug. 23, 1999.			
	C5	KWON et al., "The mouse and human genes encoding the recognition component of the N-end rule pathway", <i>Proc Natl Acad Sci, USA</i> 95:7898-7903, 1998.			
	C6	LECKER et al., "Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states", <i>J Nutr</i> 129:227S-237S, 1999.			
	C7	MATSUMOTO et al., "Tumor inoculation site-dependent induction of cachexia in mice bearing colon 26 carcinoma", <i>Brit J Cancer</i> 79:764-769, 1999.			
	C8	MITCH et al., "Mechanisms of muscle wasting: the role of ubiquitin-proteasome pathway", <i>New England J Med</i> 335:1897-1905, 1996.			
	C9	REISS et al., "Affinity purification of ubiquitin-protein ligase on immobilized protein substrates", <i>J Biol Chem</i> 265:3685-3690, 1990.			
	C10	SOLOMON et al., "Rates of ubiquitin conjugation increase when muscles atrophy, largely through activation of the N-end rule pathway", <i>Proc Natl Acad Sci USA</i> 95:12602-12607, 1998.			
	C11	STRAUSBERG et al., Database GenBank. Accession No. AI361043, Feb. 15, 1999.			
	C12	TANAKA et al., "Experimental cancer cachexia induced by transplantable colon 26 adenocarcinoma in mice", <i>Cancer Res</i> 50: 2290-2295, 1990.			
	C13	WILSON et al., "2.2 Mb of contiguous nucleotide sequence from chromosome III of <i>C. elegans</i> ", <i>Nature</i> 368:32-38, 1994.			

Examiner Signature	Date Considered
--------------------	-----------------

* Did not receive any NPL.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/758,636
<i>(Use as many sheets as necessary)</i>				Filing Date	January 15, 2004
				First Named Inventor	Hui-Quan Han
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	01017/35966C

C14	Database GenBank. National Library of Medicine, (Bethesda, Maryland, US), Accession No. U88308, The C. elegans Sequencing Consortium, "Genome sequence of the nematode C. elegans: a platform for investigating biology: the C. elegans sequencing consortium", Science 282:2012-2018, 1998.
C15	Database GenBank. National Library of Medicine, (Bethesda, Maryland, US), Accession No. AF061555, Kwon et al., "The mouse and human genes encoding the recognition component of the N-end rule pathway", Proc Natl Acad Sci USA 95:7898-7903, 1998.
C16	Database GenBank. National Library of Medicine, (Bethesda, Maryland, US), Accession No. AI187306, Strausberg, qc28h08.x1 Soares_testis_NHT Homo sapiens cDNA clone IMAGE:1751391 3', mRNA sequence; National Cancer Institute, Cancer Genome Anatomy Project, 1997.
C17	Database GenBank. National Library of Medicine, (Bethesda, Maryland, US), Accession No. AI192195, Strausberg, qc92e08.x1 Soares_pregnant_uterus_NbHPU Homo sapiens cDNA clone IMAGE:1721702 3' similar to TR:O15057 O15057 KIAA0349; mRNA sequence; National Cancer Institute, Cancer Genome Anatomy Project, 1997.
C18	Database GenBank. National Library of Medicine, (Bethesda, Maryland, US), Accession No. AI400279, Strausberg, tg43b12.x1 Soares_NFL_T_GBC_S1 Homo sapiens cDNA clone IMAGE:2111519 3', mRNA sequence; National Cancer Institute, Cancer Genome Anatomy Project, 1997.
C19	Database GenBank. National Library of Medicine, (Bethesda, Maryland, US), Accession No. AA002347, Marra et al., mg53g07.r1 Soares mouse embryo NbME13.5 14.5 Mus musculus cDNA clone IMAGE:427548 5' similar to gb:U24428 Mus musculus mu-class glutathione S-transferase (MOUSE); mRNA sequence, The WashU-HHMI Mouse EST Project, 1996.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Date Considered
--------------------	-----------------